OTLC Company Profile and Key Details

Oncotelic Therapeutics, Inc. has 457.51 million shares outstanding. The public float is 236.27 million shares, elevated short interest at 2.50% of float. This equals 662.75 thousand shares. The short ratio is 8.04 days. Institutional investors hold 0.0% of the float. Insiders own 44.89%. Trieu Vuong holds 94.12 million shares, Park Chulho has 2.83 million shares and SODERBERG PER OLOF has 650.00 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

The stock is currently mid-range between its 52-week high and low $0.02 and $0.11. With a market capitalization of about $13.31 million, Oncotelic Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.21). Key stats such as the average daily volume over the past year has been around 249.92 thousand shares, in line with its 52-week average. Headquartered in Agoura Hills, CA, Oncotelic Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Vuong Trieu, the company employs approximately 41 people and listed since August 26, 1993. Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions.

Average 10-day trading volume of 172.97 thousand shares is below the 3-month average of 249.31 thousand, indicating normal recent market interest.

Oncotelic Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.03. This means the shares are trading below this model’s fair value.

Oncotelic Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by -4338050.0%. The prior quarter beat by 24715650.0%. Over the last six quarters, Apple has recorded several small beats. These include 50.0% in May 24, 2021.

Our AI price prediction model suggests that Oncotelic Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Valuation shows Oncotelic Therapeutics, Inc. trading at a premium to the broader market with a P/E of 0.05.

Oncotelic Therapeutics, Inc. trades at a P/E ratio of 0.05, slightly below the S&P 500 average, with a price-to-sales ratio of 53.23 The P/FCF stands at -8.73, also below market averages.